BLAINJECTIONINJECTABLE
Approved
May 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
FYLNETRA (pegfilgrastim) by Kashiv BioSciences is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Approved for chemotherapy-induced neutropenia. First approved in 2022.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FYLNETRA (pegfilgrastim) is a pegylated granulocyte colony-stimulating factor (G-CSF) indicated for chemotherapy-induced neutropenia across 17 cancer types including breast, ovarian, lung, and hematologic malignancies. It works by binding to cell surface receptors on hematopoietic cells to stimulate proliferation, differentiation, and functional activation of neutrophils. The drug is administered via subcutaneous injection and is designed to reduce infection risk in cancer patients undergoing chemotherapy.
$0.081BPart D
PeakFYLNETRA is in peak lifecycle phase with 22 linked positions, suggesting a mature commercial infrastructure focused on manufacturing excellence and quality systems rather than market expansion.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications (1)
Clinical Trials (20)
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
Started Apr 2025
18 enrolled
Preeclampsia
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
Started Apr 2025
180 enrolled
Healthy Volunteer
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
Started Mar 2025
18 enrolled
Preeclampsia
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy
Started Nov 2023
100 enrolled
Breast Neoplasms
Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Started Dec 2021
17 enrolled
Multiple Myeloma
Worked on FYLNETRA at Kashiv BioSciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.